Healthcare
Pluri Inc.(PLUR)
Live Price
Offline$2.27
+0.89% today
1Y Change
-40.40%
Window
Jun 20, 2025 โ Jun 5, 2026
- Market Cap
- $30.00M
- Revenue Growth
- +309.8%
- EPS Growth
- +10.8%
- Dividend Yield
- 0.0%
Coverage: 241 bars ยท Jun 20, 2025 โ Jun 5, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pluri Inc. (PLUR) is a Healthcare stock with a market cap of $30.00M and listed on NASDAQ. The stock last traded around $2.27 and down 40.4% across the available one-year price window (Jun 20, 2025 โ Jun 5, 2026). Baseline metrics include revenue growth of +309.8%, EPS growth of +10.8%, a dividend yield of 0.0%. What stands out right now is revenue +309.8%, EPS +10.8%, free cash flow -8.1% with operating margin -1857.9% and ROIC -92.9%. Valuation already assumes a fairly strong business story at price/sales 20.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PLUR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+309.8% vs +7.6% peer median
Operating Margin
Below sector median
-1857.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
Q2 2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +309.8% and EPS at +10.8%, with operating margin around -1857.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -9.4% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
Q2 2026 May 11, 2026 | โ | +0.6% | -11.4% | โ |
Q2 2026 Apr 8, 2026 | +62.9% | +0.9% | +3.0% | -1.8% |
Q4 2025 Nov 12, 2025 | +12.2% | -6.1% | -19.8% | -30.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PLUR
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PLUR Max Drawdown
-60.28%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PLUR and SPY.
Company Overview
Pluri Inc.
NASDAQ Global Market
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
- Leadership
- Yaacov Yanay
- IPO Date
- Jun 30, 2003
- Employees
- 106
- Street Address
- Building No. 5
- Mailing
- Haifa, 3508409
- Region
- Haifa, IL
- Reporting Currency
- USD
- Investor Line
- 972 7 4710 8600
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 20.4
- Price/Book
- โ
Growth
- Revenue
- +309.8%
- EPS
- +10.8%
- Free Cash Flow
- -8.1%
Profitability
- Gross Margin
- 21.3%
- Operating Margin
- -1857.9%
- Net Margin
- -1952.1%
- ROE
- 280.4%
- ROIC
- -92.9%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.43
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.